What is Roth Capital’s Estimate for Stryker Q1 Earnings?

Stryker Co. (NYSE:SYK) – Research analysts at Roth Capital issued their Q1 2025 earnings per share estimates for Stryker in a report released on Wednesday, January 29th. Roth Capital analyst J. Wittes expects that the medical technology company will post earnings of $2.98 per share for the quarter. The consensus estimate for Stryker’s current full-year earnings is $12.06 per share. Roth Capital also issued estimates for Stryker’s Q2 2025 earnings at $3.13 EPS, Q3 2025 earnings at $3.32 EPS, Q4 2025 earnings at $4.07 EPS, FY2025 earnings at $13.50 EPS and FY2026 earnings at $14.95 EPS.

A number of other research firms also recently weighed in on SYK. Evercore ISI lifted their price objective on Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. BTIG Research boosted their price target on Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. The Goldman Sachs Group increased their price objective on Stryker from $384.00 to $427.00 and gave the stock a “neutral” rating in a research note on Thursday. JPMorgan Chase & Co. boosted their target price on shares of Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, Citigroup increased their target price on shares of Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Five research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $416.40.

Stryker Price Performance

NYSE:SYK opened at $390.48 on Thursday. The company has a market capitalization of $148.86 billion, a price-to-earnings ratio of 41.85, a PEG ratio of 2.68 and a beta of 0.95. The company has a 50-day moving average of $376.55 and a 200-day moving average of $362.18. Stryker has a 52 week low of $314.93 and a 52 week high of $406.19. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.07% and a net margin of 16.34%. During the same period last year, the business earned $3.46 earnings per share.

Hedge Funds Weigh In On Stryker

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SYK. State Street Corp boosted its stake in Stryker by 2.2% during the 3rd quarter. State Street Corp now owns 14,582,959 shares of the medical technology company’s stock worth $5,279,788,000 after acquiring an additional 316,404 shares during the last quarter. FMR LLC boosted its position in shares of Stryker by 3.0% during the third quarter. FMR LLC now owns 7,306,994 shares of the medical technology company’s stock worth $2,639,725,000 after purchasing an additional 215,782 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Stryker by 2.5% in the 3rd quarter. Geode Capital Management LLC now owns 6,905,126 shares of the medical technology company’s stock valued at $2,484,893,000 after buying an additional 165,490 shares during the period. Parnassus Investments LLC bought a new stake in shares of Stryker in the 3rd quarter valued at $762,798,000. Finally, Janus Henderson Group PLC raised its stake in Stryker by 1.5% during the 3rd quarter. Janus Henderson Group PLC now owns 1,969,757 shares of the medical technology company’s stock worth $711,594,000 after buying an additional 28,421 shares during the period. Institutional investors own 77.09% of the company’s stock.

Insider Activity

In related news, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares of the company’s stock, valued at $36,879,954.90. The trade was a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 5.90% of the company’s stock.

Stryker Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be given a dividend of $0.84 per share. The ex-dividend date is Tuesday, December 31st. This is an increase from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. Stryker’s dividend payout ratio is presently 36.01%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.